Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy, Blood, vol.99, issue.8, pp.2670-2676, 2002. ,
DOI : 10.1182/blood.V99.8.2670
A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome, Molecular Therapy - Methods & Clinical Development, vol.3, p.16049, 2016. ,
DOI : 10.1038/mtm.2016.49
URL : https://hal.archives-ouvertes.fr/hal-01474146
Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins, Molecular Therapy, vol.19, issue.5, pp.876-885, 2011. ,
DOI : 10.1038/mt.2010.274
Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients, Molecular Therapy, vol.22, issue.11, pp.1923-1935, 2014. ,
DOI : 10.1038/mt.2014.151
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B, Blood, vol.115, issue.23, pp.4678-4688, 2010. ,
DOI : 10.1182/blood-2009-12-261156
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nature Biotechnology, vol.94, issue.1, pp.59-65, 2009. ,
DOI : 10.1172/JCI22922
Adenovirus-Associated Virus Vector???Mediated Gene Transfer in Hemophilia B, New England Journal of Medicine, vol.365, issue.25, pp.2357-2365, 2011. ,
DOI : 10.1056/NEJMoa1108046
Longterm safety and efficacy of factor IX gene therapy in hemophilia B, N. Engl. J. Med, vol.371, 1994. ,
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nature Medicine, vol.24, issue.3, pp.342-347, 2006. ,
DOI : 10.1002/hep.1840200104
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant, New England Journal of Medicine, vol.377, issue.23, pp.2215-2227, 2017. ,
DOI : 10.1056/NEJMoa1708538
Gene therapy with adeno-associated virus vector 5???human factor IX in adults with hemophilia B, Blood, vol.131, issue.9, 2017. ,
DOI : 10.1182/blood-2017-09-804419
AAV5???Factor VIII Gene Transfer in Severe Hemophilia A, New England Journal of Medicine, vol.377, issue.26, pp.2519-2530, 2017. ,
DOI : 10.1056/NEJMoa1708483
Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors, Human Gene Therapy, vol.21, issue.6, pp.704-712, 2010. ,
DOI : 10.1089/hum.2009.182
Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue, Gene Therapy, vol.20, issue.4, pp.417-424, 2013. ,
DOI : 10.1038/sj.gt.3300680
Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies, Journal of Virological Methods, vol.236, pp.105-110, 2016. ,
DOI : 10.1016/j.jviromet.2016.07.009
Mapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8, Journal of Virology, vol.86, issue.15, pp.7739-7751, 2012. ,
DOI : 10.1128/JVI.00218-12
URL : http://jvi.asm.org/content/86/15/7739.full.pdf
Capsid Antibodies to Different Adeno-Associated Virus Serotypes Bind Common Regions, Journal of Virology, vol.87, issue.16, pp.9111-9124, 2013. ,
DOI : 10.1128/JVI.00622-13
URL : http://jvi.asm.org/content/87/16/9111.full.pdf
Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy, Blood, vol.108, issue.10, pp.3321-3328, 2006. ,
DOI : 10.1182/blood-2006-04-017913
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Therapy, vol.81, issue.3, pp.288-294, 2012. ,
DOI : 10.1128/JVI.00529-07
URL : http://www.nature.com/gt/journal/v19/n3/pdf/gt201190a.pdf
Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV), Journal of Medical Virology, vol.71, issue.3, pp.406-411, 1999. ,
DOI : 10.1099/0022-1317-78-6-1441
ABSTRACT, Clinical and Vaccine Immunology, vol.18, issue.9, pp.1586-1588, 2011. ,
DOI : 10.1128/CVI.05107-11
Diverse IgG subclass responses to adeno-associated virus infection and vector administration, Journal of Medical Virology, vol.11, issue.1, pp.65-74, 2009. ,
DOI : 10.1016/j.ymthe.2005.02.014
URL : http://onlinelibrary.wiley.com/doi/10.1002/jmv.21360/pdf
The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques, Molecular Therapy, vol.18, issue.1, pp.126-134, 2010. ,
DOI : 10.1038/mt.2009.245
Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats, Hepatology, vol.24, issue.1, pp.169-175, 1996. ,
DOI : 10.1053/jhep.1996.v24.pm0008707258
Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities, Clinical & Experimental Immunology, vol.34, issue.1, pp.42-50, 2008. ,
DOI : 10.1093/alcalc/34.6.830
Clinical uses of intravenous immunoglobulin, Clinical and Experimental Immunology, vol.126, issue.1, pp.1-11, 2005. ,
DOI : 10.1016/S0887-7963(03)00038-5
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2249.2005.02834.x/pdf
Reporter System, Human Gene Therapy Methods, vol.26, issue.2, pp.45-53, 2015. ,
DOI : 10.1089/hgtb.2015.037
High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency, Gene Therapy, vol.17, issue.4, 2010. ,
DOI : 10.1182/blood-2007-03-080093
URL : http://www.nature.com/gt/journal/v17/n4/pdf/gt2009157a.pdf
, Gene Ther, vol.17, pp.503-510
Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases, Journal of Invertebrate Pathology, vol.107, pp.80-93, 2011. ,
DOI : 10.1016/j.jip.2011.05.008
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys, Science Translational Medicine, vol.109, issue.4, 2013. ,
DOI : 10.1182/blood-2006-03-010181
Regulation of Antibody Responses via Antibodies, Complement, and Fc Receptors, Annual Review of Immunology, vol.18, issue.1, pp.709-737, 2000. ,
DOI : 10.1146/annurev.immunol.18.1.709
Neutralizing B Cell Response in Measles, Viral Immunology, vol.15, issue.3, pp.451-471, 2002. ,
DOI : 10.1089/088282402760312331
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B, Blood, vol.101, issue.8, pp.2963-2972, 2003. ,
DOI : 10.1182/blood-2002-10-3296
Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric Disorders, Molecular Therapy, vol.19, issue.11, 1971. ,
DOI : 10.1038/mt.2011.157
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges, Nature Reviews Genetics, vol.6, issue.5, pp.341-355, 2011. ,
DOI : 10.1002/jgm.554
Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria, J. Hepatol, vol.65, pp.776-783, 2016. ,
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice, Blood, vol.107, issue.5, pp.1810-1817, 2006. ,
DOI : 10.1182/blood-2005-08-3229
Immune surveillance by the liver, Nature Immunology, vol.119, issue.10, pp.996-1006, 2013. ,
DOI : 10.1126/science.1092385
Liver antigen-presenting cells, Journal of Hepatology, vol.54, issue.2, pp.357-365, 2011. ,
DOI : 10.1016/j.jhep.2010.10.005
URL : https://doi.org/10.1016/j.jhep.2010.10.005
Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21), Proc. Natl. Acad. Sci. USA, 2010. ,
DOI : 10.1093/emboj/cdf691
URL : http://www.pnas.org/content/107/46/19985.full.pdf
Strategy to detect pre-existing immunity to AAV gene therapy, Gene Therapy, vol.269, issue.12, pp.768-778, 2017. ,
DOI : 10.1038/gt.2014.47
URL : https://www.nature.com/articles/gt201795.pdf
Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors, The Journal of Immunology, vol.188, issue.12, pp.6418-6424, 2012. ,
DOI : 10.4049/jimmunol.1200620
URL : http://www.jimmunol.org/content/188/12/6418.full.pdf
Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques, Molecular Therapy, vol.23, issue.6, pp.1066-1076, 2015. ,
DOI : 10.1038/mt.2015.49
Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies, Journal of Virology, vol.76, issue.5, pp.2123-2130, 2002. ,
DOI : 10.1128/jvi.76.5.2123-2130.2002
Worldwide Epidemiology of Neutralizing Antibodies to Adeno???Associated Viruses, The Journal of Infectious Diseases, vol.2, issue.3, pp.381-390, 2009. ,
DOI : 10.1126/science.1154258
Inclusion of the Hepatic Locus Control Region, an Intron, and Untranslated Region Increases and Stabilizes Hepatic Factor IX Gene Expression in Vivo but Not in Vitro, Molecular Therapy, vol.1, issue.6, pp.522-532, 2000. ,
DOI : 10.1006/mthe.2000.0075
Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors, Molecular Therapy, vol.23, issue.6, pp.1022-1033, 2015. ,
DOI : 10.1038/mt.2015.59